Research Article
Uptake and Tolerance of Chemotherapy in Elderly Patients with Small Cell Lung Cancer and Impact on Survival
Table 6
Adjusted1 hazard ratio of death of patients 75 years or older diagnosed with SCLC in 2004–2008 in Alberta, Canada, who had an oncologist-consult2.
| | Adjusted1 hazard ratio (95% CI) | value |
| ECOG Score | | = 0.02 | 0, 1, and 2 | 1 | | 3 and 4 | 2.01 (1.22, 3.31) | 0.007 | Missing | 1.59 (0.88, 2.88) | 0.12 |
| Stage | | = 0.33 | Limited | 1 | | Extensive | 1.24 (0.80, 1.92) | 0.33 |
| Age at diagnosis | | = 0.80 | 75–79 | 1 | | ≥80 | 1.06 (0.66, 1.75) | 0.80 |
| Co-morbidities | | = 0.05 | 0 or 1 | 1 | | 2 or more | 1.63 (1.00, 2.66) | 0.05 |
| Drug regimen | | = 0.82 | Cisplatin/etoposide | 1 | | Carboplatin/etoposide | 1.15 (0.5, 2.65) | 0.56 | Oral etoposide | 1.15 (0.71, 1.89) | 0.75 |
| Treatment status | | = 0.0018 | Complete/full dose | 1 | | Complete/reduced dose | 1.02 (0.57, 1.82) | 0.94 | Not completed | 2.72 (1.52, 4.87) | 0.0007 | No chemotherapy | 2.01 (0.97, 4.18) | 0.6 |
|
|
Adjusted for all variables shown in the table.
2Start time was 12 weeks after the date of the initial oncologist-consult.
|